Search
The aim of this study was to assess the relationship between dust levels and health in Indigenous children in Western Australia
Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting
Our findings suggest that utilization of IL-7 by cTFH cells affects production of IgG2 antibodies to PPV23 antigens in some HIV patients
Combining elevated CRP with the presence or absence of clinical signs/ symptoms differentiates definite bacterial from presumed viral pneumonia better than CRP alone
Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Peter Lea-Ann Ruth Richmond Kirkham Thornton MBBS MRCP(UK) FRACP PhD PhD Head, Vaccine Trials Group Co-Head, Bacterial Respiratory Infectious Disease
Janessa Lea-Ann Peter Ruth Pickering Kirkham Richmond Thornton BSc PhD PhD MBBS MRCP(UK) FRACP PhD Senior Research Fellow (currently HOT NORTH Early
Elke Lea-Ann Ruth Peter Seppanen Kirkham Thornton Richmond BSc PhD PhD PhD MBBS MRCP(UK) FRACP Program Manager, Bacterial Respiratory Infectious
Ruth Peter Thornton Richmond PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Head, Vaccine Trials Group
Otitis media (OM) is one of the most common infections in young children, arising from bacterial and/or viral infection of the middle ear. Globally, Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are the predominant bacterial otopathogens. Importantly, common upper respiratory viruses are increasingly recognized contributors to the polymicrobial pathogenesis of OM.